IL315074A - Storage systems containing cryprazine or its salts - Google Patents

Storage systems containing cryprazine or its salts

Info

Publication number
IL315074A
IL315074A IL315074A IL31507424A IL315074A IL 315074 A IL315074 A IL 315074A IL 315074 A IL315074 A IL 315074A IL 31507424 A IL31507424 A IL 31507424A IL 315074 A IL315074 A IL 315074A
Authority
IL
Israel
Prior art keywords
cariprazine
salts
depot systems
depot
systems
Prior art date
Application number
IL315074A
Other languages
English (en)
Hebrew (he)
Inventor
Shai Rubnov
Ehud Marom
Anna Gopin
Original Assignee
Mapi Pharma Ltd
Shai Rubnov
Ehud Marom
Anna Gopin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mapi Pharma Ltd, Shai Rubnov, Ehud Marom, Anna Gopin filed Critical Mapi Pharma Ltd
Publication of IL315074A publication Critical patent/IL315074A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
    • A61K47/6937—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol the polymer being PLGA, PLA or polyglycolic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nanotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IL315074A 2022-03-17 2023-02-14 Storage systems containing cryprazine or its salts IL315074A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263320706P 2022-03-17 2022-03-17
PCT/IL2023/050150 WO2023175598A1 (en) 2022-03-17 2023-02-14 Depot systems comprising cariprazine or salts thereof

Publications (1)

Publication Number Publication Date
IL315074A true IL315074A (en) 2024-10-01

Family

ID=88022782

Family Applications (1)

Application Number Title Priority Date Filing Date
IL315074A IL315074A (en) 2022-03-17 2023-02-14 Storage systems containing cryprazine or its salts

Country Status (9)

Country Link
US (2) US11931357B2 (cg-RX-API-DMAC7.html)
EP (1) EP4493274A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025509390A (cg-RX-API-DMAC7.html)
CN (1) CN119136804A (cg-RX-API-DMAC7.html)
AU (1) AU2023234747A1 (cg-RX-API-DMAC7.html)
CA (1) CA3244202A1 (cg-RX-API-DMAC7.html)
IL (1) IL315074A (cg-RX-API-DMAC7.html)
MX (1) MX2024011063A (cg-RX-API-DMAC7.html)
WO (1) WO2023175598A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12514908B2 (en) 2021-07-05 2026-01-06 Mapi Pharma Ltd. Semaglutide depot systems and use thereof
US11865213B2 (en) * 2021-07-05 2024-01-09 Mapi Pharma Ltd. Semaglutide depot systems and use thereof
CA3244202A1 (en) * 2022-03-17 2023-09-21 Mapi Pharma Ltd. DEPOSIT SYSTEMS INCLUDING CARIPRAZINE OR SALTS THEREOF
US20230372331A1 (en) * 2022-05-18 2023-11-23 Anxo Pharmaceutical Co., Ltd. Pharmaceutical composition
CN119424341A (zh) * 2023-08-02 2025-02-14 珠海市华海康医药科技有限责任公司 一种注射用药物缓释微球及其制备方法
CN117137864A (zh) * 2023-11-01 2023-12-01 山东则正医药技术有限公司 一种卡利拉嗪原位凝胶制剂及其制备方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8871241B2 (en) 2002-05-07 2014-10-28 Psivida Us, Inc. Injectable sustained release delivery devices
ES2653852T3 (es) * 2007-08-03 2018-02-09 Richter Gedeon Nyrt. Composiciones farmacéuticas que contienen ligandos del receptor de dopamina y procedimientos de tratamiento usando ligandos del receptor de dopamina
US20090275597A1 (en) * 2008-05-02 2009-11-05 Forest Laboratories Holdings Limited Methods of treating cns disorders
WO2018015915A1 (en) 2016-07-22 2018-01-25 Cadila Healthcare Limited A parenteral controlled release composition of an atypical antipsychotic agent
AU2017319728B2 (en) * 2016-08-31 2024-09-05 Mapi Pharma Ltd Depot systems comprising glatiramer acetate
CN108261394B (zh) 2017-01-04 2022-03-04 广东东阳光药业有限公司 一种盐酸卡利拉嗪注射制剂及其制备方法和用途
HUP1700253A1 (hu) 2017-06-13 2019-01-28 Richter Gedeon Nyrt Szilárd orális gyógyszerkészítmények
US11344503B2 (en) * 2019-12-13 2022-05-31 Halo Science LLC Cariprazine release formulations
WO2022003662A1 (en) * 2020-06-29 2022-01-06 Mapi Pharma Ltd. Low burst-release liraglutide depot systems
CA3244202A1 (en) * 2022-03-17 2023-09-21 Mapi Pharma Ltd. DEPOSIT SYSTEMS INCLUDING CARIPRAZINE OR SALTS THEREOF

Also Published As

Publication number Publication date
CA3244202A1 (en) 2023-09-21
MX2024011063A (es) 2024-09-23
JP2025509390A (ja) 2025-04-11
AU2023234747A1 (en) 2024-09-12
US20230293515A1 (en) 2023-09-21
WO2023175598A1 (en) 2023-09-21
EP4493274A4 (en) 2026-03-18
EP4493274A1 (en) 2025-01-22
US12251380B2 (en) 2025-03-18
US20240238280A1 (en) 2024-07-18
CN119136804A (zh) 2024-12-13
US11931357B2 (en) 2024-03-19

Similar Documents

Publication Publication Date Title
HUE065722T2 (hu) Aeroszolkészítõ összeállítások
GB201910045D0 (en) Aerosol provision systems
GB202317503D0 (en) Aerosol provison systems
GB202205700D0 (en) Aerosol provision systems
GB202103376D0 (en) Aerosol provision systems
GB202008107D0 (en) Aerosol provision systems
GB2588085B (en) Asset Tracker
GB202200777D0 (en) Aerosol provision systems
GB202112471D0 (en) Microna systems
GB2622074B (en) Cache systems
HUE062393T2 (hu) Glatiramer-acetátot tartalmazó depórendszerek
GB201914831D0 (en) Aerosol provision systems
IL308937A (en) Aerosol delivery systems
GB202017800D0 (en) Dispenser systems
GB2616447B (en) Radar systems
GB202217808D0 (en) Transportation systems
GB202211778D0 (en) Depot protection system
GB202017852D0 (en) Archorage systems
GB202215769D0 (en) Tracking system
GB202017786D0 (en) Dispenser systems
GB2593707B (en) Anchoring systems
GB202308307D0 (en) Systems
GB202100102D0 (en) Storage systems
GB202102238D0 (en) Storage systems 2
GB202117231D0 (en) Transportation systems